Company research
IONIS PHARMACEUTICALS INC
CIK 874015Updated Nov 14, 2026
IONS price & chart
Loading TradingView…
NASDAQ:IONS on TradingView ↗About the company
For more than three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.
In the news
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
8-K filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Show 5 more recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
S-8 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 3,033,091,000Source | 3,081,099,000Source | 2,994,501,000Source | 2,985,133,000Source | 2,691,128,000Source | 3,449,969,000Source | 2,812,948,000Source | 2,763,928,000Source | 3,523,836,000Source | 3,003,675,000Source | 2,990,072,000Source | 2,533,876,000Source |
| Property, Plant and Equipment, NetUSD | 106,117,000Source | 82,502,000Source | 155,131,000Source | 111,951,000Source | 75,902,000Source | 142,401,000Source | 102,925,000Source | 72,795,000Source | 123,048,000Source | 94,251,000Source | 71,043,000Source | 74,294,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 338,341,000Source | 334,605,000Source | 350,065,000Source | 297,304,000Source | 293,993,000Source | 173,381,000Source | 264,192,000Source | 348,889,000Source | 372,260,000Source | 242,077,000Source | 399,266,000Source | 276,472,000Source |
| Inventory, NetUSD | 10,470,000Source | 28,452,000Source | 50,833,000Source | 8,481,000Source | 28,723,000Source | 5,557,000Source | 11,502,000Source | 30,259,000Source | 10,048,000Source | 12,512,000Source | 28,425,000Source | 22,033,000Source |
| Assets, CurrentUSD | 2,518,993,000Source | 2,713,850,000Source | 2,491,274,000Source | 2,577,150,000Source | 2,329,383,000Source | 2,936,945,000Source | 2,418,932,000Source | 2,415,675,000Source | 2,990,635,000Source | 2,620,290,000Source | 2,641,853,000Source | 2,202,694,000Source |
| Operating Lease, Right-of-Use AssetUSD | 241,993,000Source | 164,424,000Source | 231,560,000Source | 163,933,000Source | 166,939,000Source | 235,064,000Source | 159,269,000Source | 169,431,000Source | 238,549,000Source | 161,856,000Source | 171,896,000Source | 181,544,000Source |
| Other Assets, NoncurrentUSD | 165,988,000Source | 120,323,000Source | 116,536,000Source | 132,099,000Source | 118,904,000Source | 135,559,000Source | 131,822,000Source | 106,027,000Source | 171,604,000Source | 127,278,000Source | 105,280,000Source | 75,344,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 2,415,124,000Source | 2,418,631,000Source | 2,554,764,000Source | 2,353,409,000Source | 2,427,430,000Source | 2,958,555,000Source | 2,337,222,000Source | 2,467,413,000Source | 3,034,747,000Source | 2,415,324,000Source | 2,603,386,000Source | 1,960,989,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 161,000Source | 158,000Source | 166,000Source | 159,000Source | 146,000Source | 166,000Source | 159,000Source | 146,000Source | 163,000Source | 158,000Source | 144,000Source | 142,000Source |
| Retained Earnings (Accumulated Deficit)USD | -2,401,801,000Source | -2,145,459,000Source | -2,838,369,000Source | -2,273,195,000Source | -2,004,979,000Source | -2,723,723,000Source | -2,396,746,000Source | -1,938,714,000Source | -2,631,195,000Source | -2,249,808,000Source | -1,795,911,000Source | -1,429,625,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -25,978,000Source | -24,173,000Source | -33,897,000Source | -27,987,000Source | -34,838,000Source | -31,023,000Source | -28,949,000Source | -34,964,000Source | -25,281,000Source | -30,811,000Source | -32,645,000Source | -57,480,000Source |
| Stockholders' Equity Attributable to ParentUSD | 617,967,000Source | 662,468,000Source | 439,737,000Source | 631,724,000Source | 263,698,000Source | 491,414,000Source | 475,726,000Source | 296,515,000Source | 489,089,000Source | 588,351,000Source | 386,686,000Source | 572,887,000Source |
| Additional Paid in Capital, Common StockUSD | 3,045,585,000Source | 2,831,942,000Source | 3,311,837,000Source | 2,932,747,000Source | 2,303,369,000Source | 3,245,994,000Source | 2,901,262,000Source | 2,270,047,000Source | 3,145,402,000Source | 2,868,812,000Source | 2,215,098,000Source | 2,059,850,000Source |
| Liabilities and EquityUSD | 3,033,091,000Source | 3,081,099,000Source | 2,994,501,000Source | 2,985,133,000Source | 2,691,128,000Source | 3,449,969,000Source | 2,812,948,000Source | 2,763,928,000Source | 3,523,836,000Source | 3,003,675,000Source | 2,990,072,000Source | 2,533,876,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 903,456,000Source | 304,566,000Source | 315,638,000Source | 897,236,000Source | 306,162,000Source | 716,591,000Source | 250,293,000Source | 327,648,000Source | 781,567,000Source | 309,318,000Source | 448,090,000Source | 311,561,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | — | — | — | — | — | 9,509,000Source | 9,064,000Source | 8,094,000Source | 7,215,000Source |
| Accounts Payable, CurrentUSD | 14,326,000Source | 9,052,000Source | 47,704,000Source | 22,800,000Source | 9,243,000Source | 26,030,000Source | 17,456,000Source | 13,082,000Source | 28,082,000Source | 42,964,000Source | 26,027,000Source | 17,921,000Source |
| Operating Lease, Liability, NoncurrentUSD | 262,672,000Source | 168,372,000Source | 262,476,000Source | 164,379,000Source | 166,438,000Source | 259,215,000Source | 159,392,000Source | 168,674,000Source | 262,383,000Source | 161,805,000Source | 170,875,000Source | 178,941,000Source |
| Other Liabilities, NoncurrentUSD | 28,785,000Source | 41,735,000Source | 28,435,000Source | 59,074,000Source | 41,773,000Source | 28,274,000Source | 55,671,000Source | 41,800,000Source | — | — | — | 7,126,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 99,310,000Source | 124,396,000Source | 115,778,000Source | 98,957,000Source | 114,330,000Source | 126,549,000Source | 102,735,000Source | 106,048,000Source | 106,089,000Source | 108,438,000Source | 147,894,000Source | 140,101,000Source |
| Long-term Debt, Excluding Current Maturities | — | — | — | — | — | — | — | — | —Source | —Source | —Source | —Source |
| Long-term Debt, Current MaturitiesUSD | — | — | — | — | — | — | — | — | 432,120,000Source | 165,000Source | 157,000Source | 151,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | — | — | — | — | — | — | 1,327,999,000Source | 1,202,405,000Source | 1,241,004,000Source | 1,175,725,000Source |
| Short-term InvestmentsUSD | 1,901,830,000Source | 2,148,671,000Source | 1,704,520,000Source | 1,992,676,000Source | 1,784,693,000Source | 1,745,732,000Source | 1,880,960,000Source | 1,857,327,000Source | 2,305,176,000Source | 2,055,579,000Source | 1,931,935,000Source | 1,710,397,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | -269,722,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 43,275,000Source | 29,718,000Source | 133,874,000Source | 130,200,000Source | 105,809,000Source | 100,264,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -338,000Source | -1,010,000Source | 13,674,000Source | 5,071,000Source | 6,392,000Source | -2,773,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -3,095,000Source | -25,968,000Source | -15,360,000Source | 15,990,000Source | 8,119,000Source | 1,094,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -792,819,000Source | -150,775,000Source | -268,583,000Source | -500,947,000Source | -307,513,000Source | -274,370,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 536,820,000Source | 170,459,000Source | -277,776,000Source | -134,027,000Source | -214,127,000Source | -262,636,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 21,763,000Source | 12,577,000Source | 51,444,000Source | 45,280,000Source | 23,805,000Source | 15,721,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 10,953,000Source |
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 57,258,000Source | 2,199,000Source | 675,840,000Source | 478,058,000Source | 644,082,000Source | -55,295,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -198,879,000Source | 22,115,000Source | 130,183,000Source | -157,189,000Source | 122,794,000Source | -592,719,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 338,341,000Source | 334,605,000Source | 350,065,000Source | 297,304,000Source | 173,381,000Source | 264,192,000Source | 372,260,000Source | 242,077,000Source | 399,266,000Source | 276,472,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 90,000Source | 92,000Source | 10,782,000Source | 10,869,000Source | 6,512,000Source | 2,898,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | -8,000Source | -400,000Source | -639,000Source | -5,620,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 31,146,000Source | 31,984,000Source | 45,595,000Source | 29,690,000Source | 43,275,000Source | 29,718,000Source | 133,874,000Source | 130,200,000Source | 105,809,000Source | 100,264,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | 2,349,000Source | 1,642,000Source | 6,908,000Source | 6,690,000Source | 6,330,000Source | 5,373,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 661,000Source | 582,000Source | 2,439,000Source | 2,336,000Source | 2,559,000Source | 2,415,000Source |
| DepreciationUSD | — | — | — | — | — | — | 3,301,000Source | 2,228,000Source | 10,008,000Source | 9,614,000Source | 10,292,000Source | 14,328,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | — | — | — | — | — | 3,991,000Source | -7,404,000Source | -16,649,000Source | -531,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | — | -12,000Source | -161,000Source | 149,604,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | 29,908,000Source | 879,000Source | -10,182,000Source | -18,312,000Source | 22,583,000Source | -2,164,000Source | 10,220,000Source | -2,889,000Source | -1,914,000Source | -7,333,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 13,389,000Source | 0Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | 40,000Source | 61,000Source | 986,000Source | 3,032,000Source | 1,661,000Source | 2,030,000Source |
| Income Tax Expense (Benefit)USD | — | — | 213,000Source | -3,621,000Source | 1,264,000Source | -20,000Source | 218,000Source | 116,000Source | 1,786,000Source | -6,171,000Source | 32,321,000Source | 11,737,000Source |
| Induced Conversion of Convertible Debt ExpenseUSD | — | — | — | — | — | — | — | — | 16,344,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -128,606,000Source | -140,480,000Source | -114,646,000Source | 123,551,000Source | -92,528,000Source | -146,938,000Source | -381,387,000Source | -453,897,000Source | -366,286,000Source | -269,722,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 26,000,000Source | 23,200,000Source | 23,100,000Source | 8,300,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 363,000Source | 142,000Source | 987,000Source | 102,000Source | -456,000Source | 465,000Source | -15,358,000Source | 1,343,000Source | 14,256,000Source | -7,274,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 0Source | 489,120,000Source | — | — |
| Realized Investment Gains (Losses)USD | — | — | — | — | — | — | 22,583,000Source | -1,849,000Source | 9,280,000Source | -2,892,000Source | -1,589,000Source | -224,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | — | — | 31,581,000Source | 32,490,000Source | 45,595,000Source | 30,199,000Source | 43,293,000Source | 30,209,000Source | 135,664,000Source | 130,999,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | — | —Source | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 156,719,000Source | 133,814,000Source | 267,949,000Source | 452,049,000Source | 246,091,000Source | 131,612,000Source | 943,711,000Source | 705,138,000Source | 787,647,000Source | 587,367,000Source |
| Cost of RevenueUSD | — | — | 2,338,000Source | 1,071,000Source | 2,739,000Source | 4,151,000Source | 2,983,000Source | 1,463,000Source | 15,909,000Source | 11,215,000Source | 9,133,000Source | 14,116,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 96,809,000Source | 61,638,000Source | 150,396,000Source | 90,622,000Source | 150,359,000Source | 76,250,000Source | 393,867,000Source | 267,474,000Source | 232,619,000Source | 150,295,000Source |
| Operating Income (Loss)USD | — | — | -160,182,000Source | -148,656,000Source | -102,293,000Source | 139,816,000Source | -117,424,000Source | -146,860,000Source | -381,684,000Source | -475,081,000Source | -353,730,000Source | -410,191,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 363,000Source | 142,000Source | 987,000Source | 102,000Source | -456,000Source | 465,000Source | -15,358,000Source | 1,343,000Source | 14,256,000Source | -7,274,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -128,393,000Source | -144,101,000Source | -113,382,000Source | 123,531,000Source | -92,310,000Source | -146,822,000Source | -379,601,000Source | -460,068,000Source | -333,965,000Source | -257,985,000Source |
| Income Tax Expense (Benefit)USD | — | — | 213,000Source | -3,621,000Source | 1,264,000Source | -20,000Source | 218,000Source | 116,000Source | 1,786,000Source | -6,171,000Source | 32,321,000Source | 11,737,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -128,606,000Source | -140,480,000Source | -114,646,000Source | 123,551,000Source | -92,528,000Source | -146,938,000Source | -381,387,000Source | -453,897,000Source | -366,286,000Source | -269,722,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.8Source | -0.95Source | -0.69Source | 0.78Source | -0.56Source | -0.93Source | -2.38Source | -3.04Source | -2.56Source | -1.9Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.8Source | -0.95Source | -0.69Source | 0.7Source | -0.56Source | -0.93Source | -2.38Source | -3.04Source | -2.56Source | -1.9Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 159,765,000Source | 148,593,000Source | 165,419,000Source | 159,137,000Source | 164,874,000Source | 158,735,000Source | 160,010,000Source | 149,514,000Source | 143,190,000Source | 141,848,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 159,765,000Source | 148,593,000Source | 165,419,000Source | 182,331,000Source | 164,874,000Source | 158,735,000Source | 160,010,000Source | 149,514,000Source | 143,190,000Source | 141,848,000Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 661,000Source | 582,000Source | 2,439,000Source | 2,336,000Source | 2,559,000Source | 2,415,000Source |
| Costs and ExpensesUSD | — | — | 316,901,000Source | 282,470,000Source | 370,242,000Source | 312,233,000Source | 363,515,000Source | 278,472,000Source | 1,325,395,000Source | 1,180,219,000Source | 1,141,377,000Source | 997,558,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 1,786,000Source | -6,171,000Source | 32,321,000Source | 11,737,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | 29,908,000Source | 879,000Source | -10,182,000Source | -18,312,000Source | 22,583,000Source | -2,164,000Source | 10,220,000Source | -2,889,000Source | -1,914,000Source | -7,333,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -381,180,000Source | -460,712,000Source | -334,707,000Source | -258,493,000Source |
| Interest ExpenseUSD | — | — | 4,212,000Source | 4,161,000Source | 4,618,000Source | 4,114,000Source | 5,160,000Source | 4,108,000Source | 17,262,000Source | 16,994,000Source | 12,660,000Source | 8,122,000Source |
| Investment Income, NetUSD | — | — | 23,682,000Source | 26,228,000Source | 20,230,000Source | 24,687,000Source | 25,484,000Source | 24,667,000Source | 97,765,000Source | 107,022,000Source | 89,041,000Source | 25,331,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 26,000,000Source | 23,200,000Source | 23,100,000Source | 8,300,000Source |
| Realized Investment Gains (Losses)USD | — | — | — | — | — | — | 22,583,000Source | -1,849,000Source | 9,280,000Source | -2,892,000Source | -1,589,000Source | -224,000Source |
| Research and Development ExpenseUSD | — | — | — | — | — | — | — | — | 915,619,000Source | — | — | — |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | — | — | 31,581,000Source | 32,490,000Source | 45,595,000Source | 30,199,000Source | 43,293,000Source | 30,209,000Source | 135,664,000Source | 130,999,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | — | —Source | — | — | — | — | — | — |
Filing attachments
ef20085128_ex99-1.htm · 8-K · 2026-11-09
Exhibit 99.1 Ionis reports third quarter 2026 financial results and highlights progress on key programs - ZANVASTROTM (zilganersen) first approved medicine for Alexander disease; first independent launch underway from leading neurology pipeline - - TRYNGOLZA® (olezarsen) 2026 product sales guidance lowered as sHTG launch ramps more gradually than expected reflecting early dynamics of establishing a new treatment paradigm - - DAWNZERA® (donidalorsen) launch momentum continues; reaffirming 202…
Read attachment ↗ef20084325_ex99-1.htm · 8-K · 2026-10-23
Exhibit 99.1 Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN) - Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria, a key indicator of kidney damage, relative to placebo at 37 weeks with consistent treatment effects across all prespecified patient subgroups - - Sefaxersen inhibits complement factor B production and has the potential to reduce kidney inflammation and slow IgAN d…
Read attachment ↗ef20082626_ex99-1.htm · 8-K · 2026-09-23
Exhibit 99.1 Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN) - Sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential - - IgAN is a progressive kidney disease that is typically diagnosed in young adults and up to 50% of people progress to kidney failure within 20 years, requiring dialysis or transplantation - - Interim d…
Read attachment ↗ef20081690_ex99-1.htm · 8-K · 2026-09-04
EX-99.1 2 ef20081690_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) CARLSBAD, Calif., September 4, 2026 -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Novartis today announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did not meet its primary endpoint of reducing the risk of cardiovas…
Read attachment ↗ef20081649_ex99-1.htm · 8-K · 2026-09-04
EX-99.1 2 ef20081649_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients - Provides a clinically meaningful impact on motor function and a favorable impact on other symptoms seen in AxD, an ultra-rare, progressive and often fatal neurological disorder - - Priority Review Voucher (PRV) awarded in conjunction with approval - - ZANVASTRO marks Ionis’ fi…
Read attachment ↗ef20079139_ex107.htm · S-8 · 2026-07-31
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Ionis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: New Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Maximum Aggregate Fee Rate Amount of Registration Fee …
Read attachment ↗